European Union

Interview with Fred Roeder, an overview of the European medication Market

European elections 2019: science at the polls

In the context of the European elections, European Scientist is bringing you an overview of experts from different countries on various topics around science and science policy in Europe, in order to provide a panorama and analysis, which will be useful for the next commission.

The Europeans Scientist: What does the European medication Market looks like at the moment? How about the regulation?

After the United States, Europe is the most important and innovative region for pharmaceutical breakthroughs. Five out of ten of the world’s largest pharmaceutical companies are based in Europe (though only two of them in the EU after Brexit). The regulation and access to medicines in Europe is partially regulated by the EU and partially by Member States. To understand this better it’s important to distinct between mere market authorization, which allows a drug manufacturer to sell its product in a country and pricing and reimbursement decisions which determine the price of the drug and whether the public health insurance covers it.

Market access decisions are either made by the EU or at least regulated uniformly. While the European Medicines Agency (EMA) is currently busy with moving from London to Amsterdam, it has also a central role in the medicines approval system within the EU, Iceland, Liechtenstein, and Norway. If a pharmaceutical company seeks marketing authorization for an innovative drug in even just one EU Member State it has (in most cases) to apply centrally at the EMA for a marketing authorization. Generics and other medicines can be approved by national medicines agencies through either a decentralized method or by mutual recognition of existing marketing approvals in other Member States.

The decision on how much a pharmaceutical company, a wholesaler, and pharmacies can actually charge for drugs is made on either member state level or even on lower regional levels. Traditionally wealthier countries pay higher prices for drugs and cover more innovative medicine than less wealthy member states. There has been recently a push by Italy and also the World Health Organization to bring price controls on to a supranational level. Several EU countries already collaborate in the hope to have a higher bargaining power against pharmaceutical companies in the price negotiations.

ES: Is there a model to follow? Do you recommend more regulation and harmonisation or do you think that each state should keep its difference?

Different numbers show that innovative pharmaceutical companies make over 50% of their global profits in the United States. This has historically allowed Europe to have lower drug prices than the US. The current aggressive moves to bring drug prices even further down in several EU countries might severely harm the future pipeline for innovation in Europe. As a patient I am of course interested in cost control but I am even more interested in new drugs that are able to cure diseases we currently can’t treat. Many politicians run a populist train of cutting profits for pharmaceutical companies. This sounds first sexy but might jeopardize future scientific breakthroughs.

ES: What are your recommendations for the next Commission?

During the stalled TTIP talks there were good idea about more regulatory harmonization between the US FDA and Europe’s EMA. It would be good if the next Commission picks up these conversations and pushes for mutually recognizing market approvals of FDA and EMA. This would put both regulators under competitive pressure: Drug companies would seek approval first at the regulator that promises a better market approval process. Patients in this jurisdiction would benefit from life-saving innovative drugs being earlier available. Another important area were we still need improvements is to allow more patients to have access to potentially life-saving drugs that have not been approved by regulators yet. This is called compassionate use – One of these programs got recently approved in the United States and is called Right to Try. A terminally ill patient should have the right to try experimental (and potential unsafe) medicine if there’s a chance that this drug would save his or her life.  At the same time the Commission should refrain from pushing for unified drug prices in the EU.

Right now less affluent Member States benefit from high drug prices in the ‘North’. If there’s regulatory push to bring drug prices down to the smallest common denominator we risk that some innovative medicines companies just pull out of Europe entirely or massively delay the launch of their drugs in Europe.

Fred Roeder is a Health Economist and Managing Director of the Consumer Choice Center

Read more here

#JunkScience is entering courtrooms at expense of consumers

One of the most notable features of modern politics is how much easier it is today to be ‘involved’ in one way or another. That’s great. I’ve personally spent much of my energy in the past couple of years campaigning for better political education and other policies which do exactly that. Today, you can reach thousands of people through social media and have genuine influence with a single vote being cast for you – or by having any real-life experience in the areas you criticize, writes Matt Gillow.

One of the dark sides to that, however, is that much is commented on instantaneously – and people are encouraged to think with their gut in a split-second. That’s what gets retweets. All too often, lawmakers are basing their judgement on emotion and how social media will react, rather than cold, hard evidence and scientific fact.

The recent European Court of Justice ruling, which obliged the European Food Safety Authority to release a wealth of commercially sensitive data on the pesticide glyphosate, is the perfect example of split-second decision making which fails to pay heed to the evidence. Whilst encouraging greater transparency for consumers to make decisions is a good thing, the ruling raises intellectual property issues, acquiesces to lobbyists, and ignores the fact that many companies – which produce and sell products with pesticides like glyphosate – actually voluntarily release much of the information requested anyway. To top it all off – the ruling is based on junk science espoused by lobbyists and demonises safe products – to the detriment of the consumer.

The International Agency for Research on Cancer was instrumental in the verdict by adding glyphosate to a list of things considered carcinogenic. IARC’s list of carcinogenic products include chemicals found in carrots, celery, lettuce, jasmine tea and aloe vera – to name a few. The US House Committee on Space, Science and Technology, which has stated the IARC finding on glyphosate is an “affront to scientific integrity that bred distrust and confusion,” requested that (now former) IARC Director Christopher Wild appear before the Committee. Wild refused to testify, and his successor, Elizabete Weiderpass, has not responded.

The fundamental problem is that IARC misrepresents the relationship between hazard and risk. Risk is the hazard in question, paired with the degree of exposure to that hazard. In a practical example: a road is a hazard to pedestrians because while crossing it, you can get hit. However, identifying the real risk implies knowing whether people actually cross this street, and depends on the level of care they take while doing so.

For the agency, the best risk management process is to remove all hazards, even if their exposure doesn’t make them risky. Yes, residues of glyphosate is found in beer, but for beer to become a risk factor in relationship to glyphosate, you’d have to drink 1,000 litres a day. We’ll take it that in that particular case, it still won’t be the pesticide that will be your biggest concern.

According to science blogger The Riskmonger – Scientists working with toxic tort law firms are compelling IARC to produce monographs for the purpose of increasing their lucrative opportunities as litigation consultants. Collusion between tort lawyers and agencies such as the IARC for lucrative payouts is not only disconcerting and corrupt – but sets a horribly dangerous precedent. Any scientific innovation could soon fall victim of this procedure.

So not only has IARC become a front for junk science and peddling of bad news, but it has become a tool for trial lawyers seeking cancer findings by IARC which they then leverage in US courtrooms into multi-million dollar verdicts. In the case of school groundskeeper Dwayne Johnson vs. Monsanto, the judge ended up setting punitive damages at $39 million. By confusing hazard and risk, IARC has declared herbicides as carcinogenic when they are not.

The fact of the matter is that consumers are being peddled lies by junk science organisations, and crooked get-rich-quick litigation consultants are getting payouts off the back of dodgy opinions from IARC – with scientific research that is not backed up by their peers.

Junk science and split-second judgements based on a headline are infiltrating and harming commerce and courtrooms – and harming the consumer and taxpayer at the same time. But a move away from evidence-based policy making isn’t confined to science. In politics, legislators are increasingly voting on sentiment instead instead of taking a scientific approach.

Soundbites have infiltrated policy-making. In order to protect ordinary people and improve their daily lives – it’s absolutely essential that we make a return to evidence-based policy making when it comes to science. Instead, politicians, commentators and activists are pandering to their support base and their ideological tribes. People deserve better than policy-makers refusing to look past the headlines.

Read more here

It’s time to let Europe go supersonic

When France built its high-speed rail network, it revolutionised the way we looked at train traevl. What takes 4-5 hours by long-distance bus from Brussels to Paris can now be completed in just over an hour with a Thalys train. Dumping slow regional trains for fast and futuristic new models has brought more comfort and time-efficiency to consumers.

In aviation however, the opposite is the case. Since the 1960s, air travel hasn’t gotten any faster. According to Kate Repantis from MIT cruising speeds for commercial airliners today range between about 480 and 510 knots, compared to 525 knots for the Boeing 707, a mainstay of 1960s jet travel.

The reason for that is fuel-efficiency, which translates into cost-efficiency. While pilots have attempted to find the most efficient flight routes, it is slowing flights down which has effectively reduced fuel consumption. According to a story from NBC News in 2008, JetBlue saved about $13.6 million a year in jet fuel by adding just under two minutes to its flights.

But slowing things down doesn’t need to be the only alternative, and it will certainly shock passengers to learn that flight times are actually longer than 60 years ago. We can look at it this way: old regional trains are less electricity-consuming than current high-speed trains going at over 300 km/h, but there is precious little demand to bring travel times between Paris and London back to seven hours. In fact, as we use high-speed rail continuously, the technology improves and energy consumption is reduced. The same dynamic ought to work in aviation.

Supersonic planes have been out of the discussion in Europe for a while, but new innovations should make us reconsider our approach to this technology.

For long-distance intercontinental flights, supersonic planes cut flight time by more than half.  For instance, London-New York would go down from 7 hours to just 3 hours and 15 minutes.

Granted, the fuel-efficiency of current supersonic models isn’t yet ideal, but for a (re)emerging industry the only way from here is up. When considering the evolution of regular planes, which have become 80 per cent more efficient than the first airliners, there are good grounds for optimism about supersonic planes. What’s more, producers of supersonic planes are also supportive of alternative fuel use, a key part of the UN’s 2020 plan for carbon-neutral growth.

Faster flight times for consumers who like innovative solutions to environmental problems. What’s not to like?

The biggest catch is noise levels. As someone who grew up in a town neighbouring an airport, and having lived there almost 20 years, I know the differing views on airport noises. Many in my home village would defend the airport for economic reasons, while others would rally in associations of concerned citizens, fighting the airport one plane at a time. Over the years, their demands have found less support, because as planes became more efficient, they also made less noise.

Here is where supersonic planes aren’t starting from scratch either. While these aircrafts are louder on landing and take-off, new models, like Boom’s futuristic looking Overture,  are 100 times less noisy than the Concorde was. Furthermore, it would be important to compare those things that are comparable, in the same way that wouldn’t equate a regional jet with a large A380 with over 800 passengers. So yes, supersonic planes would be, at least for now, noisier. At the same time, the trade-off would entail faster travel times and the promise of lower emissions down the line.

The least we can do to increase consumer choice in this area is give supersonic a chance. Current regulations are not supportive of the fact that supersonic planes are fundamentally different than regular, subsonic, aircraft. There is a balance that both consumers and concerned citizens can strike, which looks at the questions of A) what we can realistically achieve in terms of reducing noise, and B) the advantageous trade-offs we’d get as a return of allowing Europe to go supersonic.

European Union Specializes in Nicotine Prohibition

Consumer Choice Center policy analyst Bill Wirtz wrote at the end of 2018 that the findings of the European Court of Justice were nothing but political due to a history of policy that prioritizes certain tobacco products over others. The FDA’s approach to regulating e-cigarettes is that the agency is down an aggressive regulatory path not too far off that of Europe’s.

Read more here

Trump’s 6-Month Window To Limit Car Imports Might Lead To A New Trade War

Washington D.C.: President Trump will give the EU and Japan six months to agree to a deal that would “limit or restrict” imports of automobiles and their parts into the US. It is claimed that car imports threaten national security since they have hurt domestic producers and their ability to invest in new technologies.

In response, Consumer Choice Center Deputy Director Yael Ossowski warned that by making such a treat, President Trump asserted his intention not to proceed with a cooperative solution. Where there is no political will to cooperate on trade, there’s an increasing possibility of a trade war.

“First and foremost, claims that car imports hurt domestic producers and their investing ability are ignorant of the interests of American consumers. Should Japan and the EU limit their supply of cars, consumers in the US will have to bear the costs in the form of higher prices. Protecting an industry at the expense of domestic consumers has never made any country better off,” said Ossowski.

“Trump’s decision will, ironically, hurt the ones it seeks to protect. The US car industry is heavily dependent on imports of car parts. If the EU and Japan limit their supply of car parts to the US market, the domestic sales and production will be restrained. The consequences will be numerous and damaging, and all Americans will have to bear them.

“Chances are high that Trump’s decision will spark a new trade war and impede international cooperation. Trade wars are always lose-lose. They must be stopped in the early stages and prevented altogether. If President Trump cares about the welfare of consumers and producers in his own country, it is high time he learned that free trade is the only way forward,” concluded Ossowski.

The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at

Read more here

Democratising travel

The #HandsOffMyCheapFlights campaign is about more than just what its name suggests. Cheap flights are what consumers know and love about air travel in the past years, but it is the overall phenomenon of democratised travel that should have us stand in awe. For people in upper-middle-class and wealthy conditions, the world was just the purchase of a ticket away for much longer. Whether it’s €300 or €30 to Milan, doesn’t really make much of a difference to them. So to the privileged (you’ll excuse the word) eye, travelling has remained the same, with one notable change: there are more people on the airport. Shockingly, it’s low-income consumers who suddenly fly into the same airport as the privileged travellers. It takes more time to get your suitcase, getting through security is a hassle, and for goodness sake, you can’t even get a seat while waiting to board.

No wonder some people are a bit annoyed. But saying that you don’t want people to fly just so that you don’t have to pay for fast-track security control isn’t marketable, so sustainability comes into play. What about all the noise and pollution? Don’t bother considering the fact that innovation in the aviation sector is continuously improving fuel efficiency, since carriers have no incentive to waste kerosene needlessly. Also, don’t mention that improved aircrafts, more efficient flight routes, and reduced speeds have made the sector much more efficient than it was 20 or 30 years ago.

That’s all a bit hyperbolic, and you’ll maybe even consider it bad faith. And maybe it is.

But for some reason, not everyone rejoices at the democratisation of travel. In a time in which the debate about inequality is so predominant, we’re not lending an ear to consumers who want to go on holidays, or visit a friend, just as much as all those with higher income than them. Modern aviation has made it possible, yet activists and governments around the world are there to roll this back.

The Consumer Choice Center fights the EU departure tax from the beginning. We will stand up for consumers who want to have choices when it comes to the means of transportation. We are making people aware that flights are emitting much less carbon than they were in the past, and that this level innovation is set to continue in the future. If however, we choose to limit this development in an effort to answer to alarmism, then we will inevitably fail.

Let’s not let that happen.

The EU’s war on harm reduction is in full swing

In 2020, the Netherlands will host the ninth conference of parties of the so-called WHO-FCTC treaty. During this conference, world leaders and public health advocates discuss the ways in which smoking prevalence can be curbed.

However, these same advocates haven’t just made their policies about actual tobacco, but also about vapour: innovative e-cigarette products come under fire, even though they are provenly less harmful and help those smokers who desire to quit. EU health commissioner Vytenis Andriukaitis and the anti-tobacco European Network for Smoking and Tobacco Prevention (ENSP) are leading the charge in this fight.

In 2015, Public Health England reported that an independent review found that vaping is at least 95 per cent safer than conventional smoking. PHE confirmed this assessment in December last year.

As a result, the UK has made tobacco harm reduction a centrepiece of its policies to reduce the smoking rate, as opposed to calls for direct cessation, which are less effective.

This is also backed by current evidence: a study funded by the National Institute for Health Research UK, titled “A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy” in the New England Journal of Medicine, analysed the behaviour of almost 900 randomised smokers. The conclusion: e-cigarettes were more effective for smoking cessation than nicotine replacement therapy.

A public consultation by the Health Information and Quality Authority in Ireland found that e-cigarettes are used by a third of smokers as cessation tools, and are twice as effective as a placebo.

In an interview with Euractiv, EU health commissioner Vytenis Andriukaitis said the exact opposite, claiming that nicotine replacement therapy was the better alternative. Andriukaitis also defended his head of cabinet, who had come under fire for calling e-cigarettes poison. The most telling quote from the Lithuanian commissioner is this one: “My question to the industry is the following: is it harmful or not to smoke? Does it cause cancer or not? Harm is harm. No matter if it’s less or more.”

That statement should make one think: here’s a European commissioner who does not believe in different degrees of harm. By that standard, we could also equate the harmfulness of eating red meat with smoking cigarettes. Both can cause cancer – and who really cares about the degree of harm caused by one or the other?

This lobby against harm reduction is coordinated by organisations such as the ENSP, which is funded by the Health and Consumer Programmes 2014-2020 of the European Union. This means that the European commissioner funds an NGO that invites the commissioner to events and features him in news articles funded by the same NGO.

It looks as if the European commission has broad support for their positions, but in reality, they are using claqueurs, which is nothing short of deception.

Andriukaitis and the ENSP are trying to change the narrative on anti-tobacco policy by framing it as a human right, and by making false statements about the science surrounding harm reduction.

In fact, their approach to anti-tobacco policy is an almost religious “if there is smoke, there must be harm”. They push policies that restrict not only consumer choice but also access to products that help those who choose to quit with innovate new solutions.

As the scientific evidence in favour of harm reduction is growing by the day, the European commission is stubbornly defending its anti-scientific approach to smoking cessation.

Yes, consumers should be able to quit smoking in a way they see fit, and that suits their needs. Restricting innovation for the sake of increasing your bucket list of “things to ban next” is not only nonsensical, it’s bad for people’s health.

The European commission should instead follow the British National Health Service’s approach to smoking cessation.

Read more here

Huawei Vodafone backdoor renews demand for better privacy rules

Luca Bertoletti
European Affairs Manager
Consumer Choice Center
[email protected]
39 3451694519

Huawei Vodafone backdoor renews demand for better privacy rules

ROME – Today it was revealed that hidden backdoors were discovered in Huawei Equipment by the mobile provider Vodafone back in 2011. 

Vodafone identified hidden backdoors in the software that could have given Huawei unauthorized access to the carrier’s fixed-line network in Italy, reports Bloomberg.

The Consumer Choice Center says this intrusion highlights the risks for consumer privacy violations and demonstrates how current legal rules are insufficient in protecting consumers’ privacy in the age of 5G technologies. 

Luca Bertoletti, European Affairs Manager at the Consumer Choice Center, reacted to the news.

“This incident should signal to Italian law enforcement agencies the importance of Italian privacy rights and the seriousness of privacy intrusions from third parties. We invite legislators from all of Europe to press telco operators to take new steps to protect consumer privacy and take fast actions to prevent future breaches of internet networks.”

“We don’t believe that banning Huawei, and starting a trade war with China, is the right way to go. Rather, we demand that all legislative bodies and law enforcement actors take action and create standards that should be guided by security certification of software and devices (like proposed in the EU’s “Cybersecurity Act”). We believe that strong encryption and secure methods of authentication should be a significant part of the effort to safeguard consumer privacy,” concluded Bertoletti.

This particular topic ties into the CCC’s Consumer Privacy note, which was released this month.

***CCC European Affairs Manager Luca Bertoletti is available to speak with accredited media on consumer regulations and consumer choice issues. Please send media inquiries HERE.***

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at

Lobby organisation hopes to promote “intelligent legalisation” in Luxembourg

According to the government’s coalition agreement, the legalisation of recreational cannabis is due to occur within the next five years.

The Consumer Choice Center is a US lobbying body which lobbies the freedoms, rights, and interests of consumers. In its own words, the organisation “empowers consumers to promote science, choice, and freedom in the marketplace.”

The organisation has decided to present its measures and experiences of an “intelligent legalisation of cannabis” to the Grand Duchy. Deputy director Yaël Ossowski highlighted that cannabis consumers especially appreciate new innovations and an intelligent legalisation.

The CCC’s Canadian representatives wanted to demonstrate the Canadian model to Luxembourgish authorities. As a result, they are visiting the Grand Duchy over three days to show the Canadian perspectives, rationale, and experiences of legalisation through press conferences and meetings. The representatives are meeting the LSAP and the trade union confederation the LCGB to spread their ideas in the hopes that the government will orientate its path around their findings.

However, Minister of Justice Felix Braz and Minister of Health Etienne Schneider, whose ministries are charged with legalisation, are not participating in the meetings.

Read more here

Luxemburg auf dem Weg zur Legalisierung: Lobby fordert verbessertes kanadisches Modell

Auf dem Weg zur Legalisierung von medizinischem und rekreativem Cannabis könnte sich die Regierung am kanadischen Modell inspirieren. Vertreter des Consumer Choice Center (CCC) besuchen derzeit Luxemburg. Die Lobbyisten wollen Entscheidern aus Politik und Gesellschaft das kanadische Modell vorstellen – und dafür werben, dass keine hohen Steuern auf Marihuana-Produkte erhoben werden.

Das CCC ist eine US-amerikanische Non-Profit-Organisation. Sein Ziel: Die Auswahl an Konsumgütern zu erhalten, die es durch staatliche Regulierung gefährdet sieht. Laut der Organisation Corporate Europe Observatory soll das CCC von der Tabaklobby und den konservativen Hardlinern Charles und David Koch finanziert werden. Seit 2017 ist die Organisation in der Europäischen Union tätig.

In Luxemburg versuchen CCC-Vertreter, mit Parteien und Ent- scheidern aus Politik und Gesellschaft Kontakt aufzunehmen. Sie wollen das kanadische Cannabis-Modell vorstellen – und warnen davor, dass der Staat zu hohe Steuern auf die Hanfprodukte erhebt. Im Oktober 2018 hat Kanada als erstes Land der Welt den Handel von Marihuana legalisiert. Cannabisprodukte werden in manchen kanadischen Provinzen teils bis zu 29 Prozent besteuert, erklärt das CCC. Die Organisation fordert, die anfallenden Steuern angemessen gering zu halten.

“Obwohl Steuereinnahmen ein wichtiger und strategischer Faktor sind, der bei der Legalisierung von Cannabis zu berücksichtigen ist, sollte es nicht das alleinige Ziel von Gesetzgebern sein, die ihre Märkte für Cannabis öffnen wollen. Durch die Beibehaltung eines niedrigen und wettbewerbsfähigen Steuersatzes kann Luxemburg den legalen Konsum ermöglichen. Dies wird sich sowohl bei den Steuererhebungen als auch für allgemeine Investitionen in der Gesamtwirtschaft positiv erweisen”, sagte David Clement, der North American Affairs Manager des CCC.

Billigstes Grad in Kanada: 7,31 Euro

Schätzungsweise die Hälfte des verkauften Cannabis in Kanada wird immer noch auf dem Schwarzmarkt umgesetzt. Der Grammpreis für das billigste Gras beträgt rund 11 kanadische Dollar (umgerechnet 7,31 Euro). Damit sich diese Situation nicht in Luxemburg wiederholt, würden die Experten der Regierung raten, Cannabisprodukte nicht zu hoch zu versteuern. Denn der Schwarzmarkt floriert, wenn viele Menschen vom legalen Handel ausgeschlossen sind. Um diesem Trend entgegenzuwirken, würde das CCC den Verkauf von Cannabisprodukten auch an Nicht-Luxemburger begrüßen.

Momentan ist es in Kanada verboten, in der Öffentlichkeit Gras zu rauchen, Coffeeshops gibt es nicht. Somit wurde einkommensschwachen Konsumenten die Möglichkeit genommen, in einem legalen Rahmen ihren Joint zu rauchen. Im Gegensatz hierzu darf jeder Volljährige zu jeder Zeit 30 Gramm Gras bei sich tragen. Das CCC schlägt vor, den Konsum von Marihuana in Luxemburg ähnlich zu reglementieren wie den Konsum von Tabak.

Keine Einzelheiten zum Gehalt

Cannabis darf momentan in Kanada legal vertrieben werden. Die Konsumenten erhalten jedoch keine Einzelheiten zum CBD- oder THC-Gehalt. CBD-Gras kann schon länger ohne Rezept in Hanfläden in Luxemburg erworben werden. CBD gilt als nicht-psychoaktives Cannabinoid – es wirkt sich also nicht auf das zentrale Nervensystem aus, weshalb die Wahrnehmung auch nicht verändert wird. Für den Rausch sorgt der Wirkstoff Tetrahydrocannabinol (THC).

Auch über die Wirkungen dürfen die Verkäufer nicht informieren. David Clement sieht hier vor allem die Erstkonsumenten unnötigen Gefahren ausgesetzt. “Ein sichtbares Branding ermöglicht es den Kunden zudem, ein Vertrauensverhältnis zu ihrer Marke aufzubauen.” Um Engpässe zu vermeiden, rät das CCC, die Zulassungslizenzen nicht zu deckeln. Ob sich die Regierung bei der Legalisierung von rekreativem Gras nur an dem aktuellen kanadischen Modell orientiert oder ob die Verbesserungsvorschläge der Experten des CCC berücksichtigt werden, ist zurzeit noch nicht absehbar.

Parlamentarische Arbeitsgruppen sind derzeit dabei, alle möglichen Optionen in Sachen Cannabis-Legalisierung abzuwägen. Gesundheitsminister Etienne Schneider wird in naher Zukunft auf jeden Fall mit einer Delegation nach Kanada reisen, um sich vor Ort ein Bild zu machen.

Continue Reading
Scroll to top